Cyhoeddiad
2023
- Taylor, P. et al. 2023. Factors predicting long-term outcome and the need for surgery in Graves orbitopathy: Extended follow-up from the CIRTED trial. The Journal of Clinical Endocrinology & Metabolism 108(10), pp. 2615-2625. (10.1210/clinem/dgad084)
2022
- Stimpson, M. L. et al. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196(4), pp. 1113-1117. (10.1111/bjh.17884)
2021
- Bradbury, C. A. et al. 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385(10), pp. 885-895. (10.1056/NEJMoa2100596)
2020
- Greenwood, R., Pell, J., Foscarini-Craggs, P., Wale, K., Thomas, I. and Bradbury, C. 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21(1), article number: 873. (10.1186/s13063-020-04798-x)
2019
- Draman, M. S. et al. 2019. Prostaglandin F2-alpha eye drops (bimatoprost) in Graves' orbitopathy: a randomized controlled double-masked crossover trial (BIMA Trial). Thyroid Journal Program 29(4), pp. 563-572. (10.1089/thy.2018.0506)
2018
- Pell, J. et al. 2018. Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. BMJ Open 8(10), article number: e024427. (10.1136/bmjopen-2018-024427)
- Rajendram, R. et al. 2018. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology 6(4), pp. 299-309. (10.1016/S2213-8587(18)30021-4)
Articles
- Taylor, P. et al. 2023. Factors predicting long-term outcome and the need for surgery in Graves orbitopathy: Extended follow-up from the CIRTED trial. The Journal of Clinical Endocrinology & Metabolism 108(10), pp. 2615-2625. (10.1210/clinem/dgad084)
- Stimpson, M. L. et al. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196(4), pp. 1113-1117. (10.1111/bjh.17884)
- Bradbury, C. A. et al. 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385(10), pp. 885-895. (10.1056/NEJMoa2100596)
- Greenwood, R., Pell, J., Foscarini-Craggs, P., Wale, K., Thomas, I. and Bradbury, C. 2020. Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK. Trials 21(1), article number: 873. (10.1186/s13063-020-04798-x)
- Draman, M. S. et al. 2019. Prostaglandin F2-alpha eye drops (bimatoprost) in Graves' orbitopathy: a randomized controlled double-masked crossover trial (BIMA Trial). Thyroid Journal Program 29(4), pp. 563-572. (10.1089/thy.2018.0506)
- Pell, J. et al. 2018. Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. BMJ Open 8(10), article number: e024427. (10.1136/bmjopen-2018-024427)
- Rajendram, R. et al. 2018. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes and Endocrinology 6(4), pp. 299-309. (10.1016/S2213-8587(18)30021-4)